Tarceva 150 mg (Tablet)
Unit Price: ৳ 3,599.76 (3 x 10: ৳ 107,992.80)
Strip Price: ৳ 35,997.60
Medicine Details
Category | Details |
---|---|
Generic | Erlotinib |
Company | Roche bangladesh ltd |
Also available as |
Therapeutic Class
- Targeted Cancer Therapy
Indications
- First-line treatment of metastatic Non-Small Cell Lung Cancer (NSCLC) with EGFR exon 19 deletions or exon 21 substitution mutations
- Maintenance treatment of locally advanced or metastatic NSCLC after four cycles of platinum-based first-line chemotherapy
- Treatment of locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen
- First-line treatment of locally advanced, unresectable, or metastatic pancreatic cancer in combination with gemcitabine
Description
- Chemical name: N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)4-quinazolinamine
- Reversibly inhibits EGFR kinase activity
- Higher binding affinity for EGFR exon 19 deletion or exon 21 (L858R) mutations than wild-type receptor
Dosage & Administration
- Recommended daily dose for NSCLC: 150 mg on an empty stomach
- Recommended daily dose for Pancreatic Cancer: 100 mg once daily in combination with gemcitabine
- Dose reduction for severe reactions with CYP3A4 inhibitors
- Dose increment for concurrent cigarette smoking or CYP3A4 inducers
Interaction
- Interaction with coumarin-derived anticoagulants leading to increased International Normalized Ratio (INR) and bleeding adverse reactions
- Metabolized predominantly by CYP3A4
- Effects of co-treatment with CYP3A4 inhibitors and inducers
- Effects of drugs affecting gastric pH on Tarceva exposure
Side Effects
- Common adverse reactions: rash, diarrhea, anorexia, fatigue, dyspnea, cough, nausea, vomiting
- Serious adverse reactions including Interstitial Lung Disease (ILD), Renal Failure, and Gastrointestinal Perforation
Pregnancy & Lactation
- Pregnancy category D
- Potential for fetal harm
- Unknown presence in human milk
Precautions & Warnings
- Risk of Interstitial Lung Disease (ILD)
- Monitoring of renal function and electrolytes
- Monitoring of liver testing
- Discontinuation in cases of ILD, renal toxicity, hepatic impairment, gastrointestinal perforations, and skin disorders
Use in Special Populations
- Safety and effectiveness in pediatric patients not established
- No overall differences in safety or efficacy in subjects aged 65 and older
Overdose Effects
- Tolerance of single oral doses up to 1,000 mg in healthy subjects
- Poor tolerance of repeated twice-daily doses above recommended levels
- Possible severe adverse reactions such as diarrhea, rash, and liver transaminase elevation
Storage Conditions
- Store at a temperature not exceeding 30°C
- Protect from light and moisture